An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
Authors
Keywords
-
Journal
Drug Design Development and Therapy
Volume Volume 15, Issue -, Pages 2987-2998
Publisher
Informa UK Limited
Online
2021-07-08
DOI
10.2147/dddt.s317382
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects
- (2021) Kyung‐Sang Yu et al. CTS-Clinical and Translational Science
- Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis
- (2020) Kelly A. Reynolds et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
- (2020) Jinmei Su et al. BIODRUGS
- The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
- (2020) Liese Barbier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
- (2020) Antonella Di Cesare et al. Dermatologic Therapy
- Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
- (2020) Cosimo Bruni et al. CLINICAL RHEUMATOLOGY
- PF-06410293: An Adalimumab Biosimilar
- (2020) Arnold Lee et al. BIODRUGS
- Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
- (2020) Valdemar Wendelboe Nielsen et al. Dermatologic Therapy
- GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
- (2019) Oliver von Richter et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States
- (2019) A. Teeple et al. CURRENT MEDICAL RESEARCH AND OPINION
- AURIEL ‐PsO: A randomised, double‐blind Phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
- (2019) J. Hercogová et al. BRITISH JOURNAL OF DERMATOLOGY
- State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis
- (2019) Paolo Gisondi et al. CURRENT OPINION IN PHARMACOLOGY
- Biosimilars for the treatment of psoriasis
- (2019) Lluís Puig et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
- (2019) Christopher J. Edwards et al. CLINICAL RHEUMATOLOGY
- Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)
- (2019) Stanley B. Cohen et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
- (2018) Stanley B Cohen et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis
- (2018) Michael E. Weinblatt et al. Arthritis & Rheumatology
- A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers
- (2017) D. Shin et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Therapy: Biosimilars in rheumatology — why, how and when in 2017
- (2017) Roy Fleischmann Nature Reviews Rheumatology
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
- (2016) Hillel Cohen et al. ADVANCES IN THERAPY
- A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
- (2016) Primal Kaur et al. ANNALS OF THE RHEUMATIC DISEASES
- Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects
- (2016) Christopher Wynne et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study
- (2015) G. Palareti et al. International Journal of Laboratory Hematology
- A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
- (2015) Rajendrakumar H. Jani et al. International Journal of Rheumatic Diseases
- Budget Impact Analysis of An Etanercept Biosimilar for The Treatment of Rheumatoid Arthritis In Europe
- (2015) L Ruff et al. VALUE IN HEALTH
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search